EHA 2025: Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL

Sonrotoclax – a next-generation, oral, selective BCL-2 inhibitor, demonstrates greater selectivity and pharmacological potency compared to venetoclax, with a shorter half-life and no observed drug accumulation. In this MEDtalk from EHA 2025, Professor Chan Y. Cheah presents updated data on sonrotoclax in combination with zanubrutinib for the treatment of relapsed/refractory CLL/SLL. The results confirm high efficacy of the combination, including in patients with high-risk disease features. Professor Cheah also shares his expert perspective on the clinical implications of these findings.